D. E. Shaw & Co. Inc. Has $4.44 Million Stock Holdings in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

D. E. Shaw & Co. Inc. increased its holdings in ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) by 27.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 288,409 shares of the company's stock after purchasing an additional 62,889 shares during the period. D. E. Shaw & Co. Inc. owned approximately 1.05% of ClearPoint Neuro worth $4,436,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. R Squared Ltd bought a new stake in shares of ClearPoint Neuro in the 4th quarter valued at approximately $32,000. AlphaQuest LLC acquired a new stake in ClearPoint Neuro in the 4th quarter valued at $80,000. Barclays PLC grew its position in ClearPoint Neuro by 24.3% in the third quarter. Barclays PLC now owns 5,674 shares of the company's stock valued at $64,000 after acquiring an additional 1,109 shares during the period. Tower Research Capital LLC TRC acquired a new position in ClearPoint Neuro during the fourth quarter worth $93,000. Finally, JPMorgan Chase & Co. raised its stake in ClearPoint Neuro by 58.7% during the third quarter. JPMorgan Chase & Co. now owns 9,770 shares of the company's stock worth $110,000 after acquiring an additional 3,612 shares in the last quarter. Institutional investors own 30.08% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. B. Riley boosted their target price on shares of ClearPoint Neuro from $15.00 to $20.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. Lake Street Capital boosted their price target on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the company a "buy" rating in a research report on Tuesday, January 21st. Finally, Stifel Nicolaus raised their price objective on shares of ClearPoint Neuro from $19.00 to $25.00 and gave the stock a "buy" rating in a report on Tuesday, April 1st.

ClearPoint Neuro Stock Performance

ClearPoint Neuro stock traded down $0.63 on Wednesday, reaching $12.16. The company's stock had a trading volume of 224,843 shares, compared to its average volume of 235,371. The business's fifty day moving average price is $12.87 and its 200 day moving average price is $14.23. The company has a market cap of $340.35 million, a price-to-earnings ratio of -17.62 and a beta of 1.03. ClearPoint Neuro, Inc. has a twelve month low of $5.11 and a twelve month high of $19.22.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.07). ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. The business had revenue of $8.49 million during the quarter, compared to the consensus estimate of $8.21 million. As a group, equities analysts forecast that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current year.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.